Selinexor is a medication being studied for its effectiveness and safety in treating patients with myelofibrosis, a type of bone marrow cancer. This trial focuses on patients who have not previously been treated with JAK inhibitors and have moderate thrombocytopenia, which means they have a lower than normal number of platelets in their blood. Selinexor is being tested as a single-agent therapy, meaning it is used alone without combining it with other treatments. The goal is to see how well it works in reducing the size of the spleen, which is a common issue in myelofibrosis patients.

Moderate Thrombocytopenia – This condition is characterized by a lower than normal number of platelets in the blood, which are essential for blood clotting. Individuals with moderate thrombocytopenia may experience symptoms such as easy bruising, frequent nosebleeds, or prolonged bleeding from cuts. The condition can arise from various causes, including certain medications, autoimmune diseases, or bone marrow disorders. It is important to monitor platelet levels to prevent complications. The progression of the condition depends on the underlying cause and the individual’s overall health.

JAK Inhibitor-Naïve Myelofibrosis – Myelofibrosis is a rare bone marrow disorder that disrupts the body’s normal production of blood cells, leading to severe anemia, weakness, and an enlarged spleen. In patients who have not previously been treated with JAK inhibitors, the disease may present with symptoms such as fatigue, night sweats, and weight loss. The condition is caused by the abnormal growth of fibrous tissue in the bone marrow, which impairs its ability to produce blood cells. Over time, myelofibrosis can lead to significant complications, including an increased risk of infections and bleeding. The progression of the disease varies among individuals, and regular monitoring is essential.